Alemtuzumab is a humanized anti-CD52 monoclonal antibody used for the treatment of high activity relapsing multiple sclerosis (R-MS). The most common adverse event is an infusion reaction due to cytokine-release. Autoimmunity can arise from months to years after treatment and encompasses Grave’s disease and thrombocytopenia. Recent reports of stroke, heart attack, and arterial dissection after alemtuzumab administration, in some cases within hours of infusion, led the European Medicines Agency’s (EMA's) Pharmacovigilance Risk Assessment Committee (PRAC) to a safety review of treatment with alemtuzumab. We report a D-Dimer increasing with suspected associated pulmonary embolism in an RMS patient after the first alemtuzumab administration. D-dimer test is not mandatory after alemtuzumab treatment, but its possible increase should warn the physician to select the patients with lower cardiovascular and thrombosis risk.
| Published in | International Journal of Clinical and Experimental Medical Sciences (Volume 5, Issue 5) |
| DOI | 10.11648/j.ijcems.20190505.12 |
| Page(s) | 67-69 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2019. Published by Science Publishing Group |
Multiple Sclerosis, Alemtuzumab, D-Dimer, Interleukin 6, Thrombosis, Biomarker, Manuscript
| [1] | H.-P. Hartung, O. Aktas, and A. N. Boyko, “Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.,” Mult. Scler., vol. 21, no. 1, pp. 22–34, Jan. 2015. |
| [2] | Y. Hu et al., “Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model,” Immunology, vol. 128, no. 2, pp. 260–270, 2009. |
| [3] | M. G. Wing et al., “Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: Involvement of CD16 (FcγRIII) and CD11a/CD18 (LFA-1) on NK cells,” J. Clin. Invest., vol. 98, no. 12, pp. 2819–2826, 1996. |
| [4] | H.-P. Hartung, O. Aktas, and A. N. Boyko, “Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis.,” Mult. Scler., no. Figure 1, pp. 1–13, 2014. |
| [5] | B. McCall, “Alemtuzumab to be restricted pending review, says EMA,” Lancet (London, England), 2019. |
| [6] | “www.ehealthme.com.” [Online]. Available: https://www.ehealthme.com/ds/campath/fibrin-d-dimer-increased/. [Accessed: 06-Jun-2019]. |
| [7] | H. A. Chakkera, A. Sharif, and B. Kaplan, “Negative Cardiovascular Consequences of Small Molecule Immunosuppressants,” Clinical Pharmacology and Therapeutics, vol. 102, no. 2. pp. 269–276, 2017. |
| [8] | B. S. Taylor et al., “HIV and Obesity Comorbidity Increase Interleukin 6 but Not Soluble CD14 or D-Dimer,” J. Acquir. Immune Defic. Syndr., vol. 75, no. 5, pp. 500–508, 2017. |
| [9] | R. Kerr, D. Stirling, and C. A. Ludlam, “Interleukin 6 and haemostasis,” British Journal of Haematology, vol. 115, no. 1. pp. 3–12, 2001. |
| [10] | S. C. Robson, E. G. Shephard, and R. E. Kirsch, “Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1β, IL-6 and plasminogen activator inhibitors from monocytes in vitro,” Br. J. Haematol., 1994. |
| [11] | D. A. Duprez et al., “Inflammation, coagulation and cardiovascular disease in HIV-infected individuals,” PLoS One, vol. 7, no. 9, 2012. |
| [12] | S. J. Piva et al., “Assessment of inflammatory and oxidative biomarkers in obesity and their associations with body mass index,” Inflammation, 2013. |
| [13] | B. Grund et al., “Relevance of interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy,” PLoS One, vol. 11, no. 5, 2016. |
APA Style
Stefania Federica De Mercanti, Simona Rolla, Manuela Matta, Marco Iudicello, Emanuele Franchin, et al. (2019). D-dimer Increasing After First Alemtuzumab Administration in a Multiple Sclerosis Patient. International Journal of Clinical and Experimental Medical Sciences, 5(5), 67-69. https://doi.org/10.11648/j.ijcems.20190505.12
ACS Style
Stefania Federica De Mercanti; Simona Rolla; Manuela Matta; Marco Iudicello; Emanuele Franchin, et al. D-dimer Increasing After First Alemtuzumab Administration in a Multiple Sclerosis Patient. Int. J. Clin. Exp. Med. Sci. 2019, 5(5), 67-69. doi: 10.11648/j.ijcems.20190505.12
AMA Style
Stefania Federica De Mercanti, Simona Rolla, Manuela Matta, Marco Iudicello, Emanuele Franchin, et al. D-dimer Increasing After First Alemtuzumab Administration in a Multiple Sclerosis Patient. Int J Clin Exp Med Sci. 2019;5(5):67-69. doi: 10.11648/j.ijcems.20190505.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijcems.20190505.12,
author = {Stefania Federica De Mercanti and Simona Rolla and Manuela Matta and Marco Iudicello and Emanuele Franchin and Marinella Clerico},
title = {D-dimer Increasing After First Alemtuzumab Administration in a Multiple Sclerosis Patient},
journal = {International Journal of Clinical and Experimental Medical Sciences},
volume = {5},
number = {5},
pages = {67-69},
doi = {10.11648/j.ijcems.20190505.12},
url = {https://doi.org/10.11648/j.ijcems.20190505.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcems.20190505.12},
abstract = {Alemtuzumab is a humanized anti-CD52 monoclonal antibody used for the treatment of high activity relapsing multiple sclerosis (R-MS). The most common adverse event is an infusion reaction due to cytokine-release. Autoimmunity can arise from months to years after treatment and encompasses Grave’s disease and thrombocytopenia. Recent reports of stroke, heart attack, and arterial dissection after alemtuzumab administration, in some cases within hours of infusion, led the European Medicines Agency’s (EMA's) Pharmacovigilance Risk Assessment Committee (PRAC) to a safety review of treatment with alemtuzumab. We report a D-Dimer increasing with suspected associated pulmonary embolism in an RMS patient after the first alemtuzumab administration. D-dimer test is not mandatory after alemtuzumab treatment, but its possible increase should warn the physician to select the patients with lower cardiovascular and thrombosis risk.},
year = {2019}
}
TY - JOUR T1 - D-dimer Increasing After First Alemtuzumab Administration in a Multiple Sclerosis Patient AU - Stefania Federica De Mercanti AU - Simona Rolla AU - Manuela Matta AU - Marco Iudicello AU - Emanuele Franchin AU - Marinella Clerico Y1 - 2019/10/11 PY - 2019 N1 - https://doi.org/10.11648/j.ijcems.20190505.12 DO - 10.11648/j.ijcems.20190505.12 T2 - International Journal of Clinical and Experimental Medical Sciences JF - International Journal of Clinical and Experimental Medical Sciences JO - International Journal of Clinical and Experimental Medical Sciences SP - 67 EP - 69 PB - Science Publishing Group SN - 2469-8032 UR - https://doi.org/10.11648/j.ijcems.20190505.12 AB - Alemtuzumab is a humanized anti-CD52 monoclonal antibody used for the treatment of high activity relapsing multiple sclerosis (R-MS). The most common adverse event is an infusion reaction due to cytokine-release. Autoimmunity can arise from months to years after treatment and encompasses Grave’s disease and thrombocytopenia. Recent reports of stroke, heart attack, and arterial dissection after alemtuzumab administration, in some cases within hours of infusion, led the European Medicines Agency’s (EMA's) Pharmacovigilance Risk Assessment Committee (PRAC) to a safety review of treatment with alemtuzumab. We report a D-Dimer increasing with suspected associated pulmonary embolism in an RMS patient after the first alemtuzumab administration. D-dimer test is not mandatory after alemtuzumab treatment, but its possible increase should warn the physician to select the patients with lower cardiovascular and thrombosis risk. VL - 5 IS - 5 ER -
Information
Email: